Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases

Summary

his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with Pseudodrusen-like Appearance (EMAP). Participants will receive three subtenon injections of autologous platelet-rich plasma (1.5 mL per injection) administered at two-month intervals (M0, M2, M4). The primary objective is to assess functional changes over a 6-month period, with a focus on visual field preservation, evaluated by the Field Preservation Deviation Index (FPDI) and Mean Deviation (MD), as well as best-corrected visual acuity (BCVA, LogMAR). Secondary outcomes include changes in 30-Hz flicker electroretinography (ERG) amplitude, structural retinal parameters on optical coherence tomography (OCT)-including central macular thickness and ellipsoid zone length-and ocular safety outcomes, such as intraocular pressure, local tolerability, and the occurrence of inflammatory or adverse events related to subtenon PRP administration.

Timeline

Start

2025-01-04

Primary completion

2026-03-04

Completion

2027-01-04

Publications

• Results Siqueira RC, Brandao CC, Souza ACJ, Seixas JR, Balbino MA, Antunes LM, Oliveira CM, Pinho TS, Cruz PF. Subtenon Autologous Platelet-Rich Plasma in Degenerative Retinal Diseases: A Prospective Pilot Study of Safety and Exploratory Functional Signals in Retinitis Pigmentosa and EMAP. Biomedicines. 2026 Apr 30;14(5):1029. doi: 10.3390/biomedicines14051029.

Drugs

Indications